All lobbying filings

THE MCMANUS GROUP

Lobbying for GENENTECH

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Apr 21, 2025

Official filing document

Bills named in this filing 1

HR 1672
Maintaining Investments in New Innovation Act

Lobbying activity 3

Medicare/Medicaid

Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 1672- Maintaining Investments in New Innovation Act. Issues related to physician reimbursement for Part B drugs.

Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.

Taxation/Internal Revenue Code

Issues related to tax exempt hospitals and charity care. Issues related to corporate tax reform.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.